The State Food and Drug Administration (SFDA) issued the No.51 Drug Administrative Protection Announcement on March 9, 2005, declaring the ending of drug administrative protection for Glaxo Wellcome GmbH & Co.'s Cutivate Cream  (fluticasone propionate).